Refractory Diffuse Large B-cell Lymphoma

Refractory Diffuse Large B-cell Lymphoma After First-line Immuno-CT: Treatment Options and Outcomes

In the rituximab era, one-third of diffuse large B-cell lymphoma (DLBCL) patients experience relapse/refractory disease after first-line anthracycline-based immunochemotherapy (IChemo). Optimal management remains an unmet medical need. The aim of this study was to report the outcomes of a cohort of refractory patients according to their patterns of refractoriness and the type of salvage option. The investigators performed a retrospective analysis, which included 104 DLBCL patients treated at Lyon Sud University Hospital (2002-2017) who presented with refractory disease. The investigators retrospectively evaluated the outcomes of a cohort of 104 refractory patients according to their patterns of refractoriness and the type of salvage option.

Inclusion Criteria:

-≥18 years of age

• diagnosed with DLBCL at Lyon Sud University Hospital (LSUH) from January 2002 to January 2017
• presented with refractory disease in response to front-line therapies
• including anthracycline-based chemo and a monoclonal anti-CD20 antibody

Exclusion Criteria:

• Patients with a history of indolent lymphoma,
• Patients with a primary central nervous system (CNS) lymphoma or immunosuppression-related lymphoma